JCO Article Insights: Duvelisib in Patients with Relapsed or Refractory PTCL
In this episode of JCO Article Insights, host Ash Gurumurthi summarizes the article "Duvelisib Induces Deep Responses in Peripheral T-Cell Lymphoma: Final Results of the Phase II PRIMO Trial of Duvelisib in Relapsed/Refractory Peripheral T-Cell Lymphoma," by Mehta-Shah and colleagues. LINK TO FULL TRANSCRIPT
Podzilla Summary coming soon
Sign up to get notified when the full AI-powered summary is ready.
Free forever for up to 3 podcasts. No credit card required.
Listen to This Episode
More from Journal of Clinical Oncology (JCO) Podcast
Effectiveness of a Virtual Tobacco Treatment for Cancer Patients
Phase 2 Study of Multi-Cancer Detection from Breath Samples
JCO at ASCO 2026: Individualized Neoantigen Therapy Plus Pembrolizumab in Melanoma
JCO at ASCO 2026: Pemigatinib Phase 3 FIGHT-302 Trial in Cholangiocarcinoma
Get summaries like this every morning.
Free AI-powered recaps of Journal of Clinical Oncology (JCO) Podcast and your other favorite podcasts, delivered to your inbox.
Free forever for up to 3 podcasts. No credit card required.